Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.52 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035812 | 1.00 | FURIN (0.52) | FURINPCSK6SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL9495059 | 0.92 | FURIN (0.45) | FURINPCSK6SIRT6SIRT1ALDH1A1 | |
| SCHEMBL9495080 | 0.92 | FURIN (0.45) | FURINPCSK6SIRT6SIRT1ALDH1A1 | |
| SCHEMBL29514837 | 0.87 | SMN1; SMN2 (0.46) | FURINPCSK6SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL11094153 | 0.84 | SMN1; SMN2 (0.42) | FURINPCSK6SMN1; SMN2 | |
| SCHEMBL26429404 | 0.83 | FURIN (0.44) | FURINPCSK6 | |
| SCHEMBL25519403 | 0.81 | CTSK (0.43) | FURINPCSK6SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL8387889 | 0.80 | CTSK (0.57) | ALDH1A1CTSKCTSL | |
| SCHEMBL8695376 | 0.80 | CTSK (0.57) | ALDH1A1CTSKCTSL | |
| SCHEMBL8972183 | 0.80 | CTSK (0.57) | ALDH1A1CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | UNIV CHICAGO (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4208174-A2 | NUCLEIC ACID-DERIVATIZED THERAPEUTICS | The University of Chicago (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116367849-A | Therapeutic agent derived from nucleic acid | 芝加哥大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | FURIN 55/4885PCSK6 246/4885SMN1; SMN2 902/4885 |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | NSUN2, NSUN3, POLRMT | FURIN 1207/4885PCSK6 2340/4885SMN1; SMN2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.